Hyperbaric oxygen therapy for radiation-induced injury: evidence is needed  by Creutzberg, Carien L
Comment
132 www.thelancet.com/oncology   Vol 17   February 2016
Many patients with gynaecological cancers, 
colorectal cancers, and genitourinary cancers receive 
radiation therapy as primary or adjuvant treatment. 
Despite improvements in radiation techniques, a 
substantial subgroup of these patients have chronic 
radiation-induced gastrointestinal symptoms that 
strongly aﬀ ect their daily lives. Hyperbaric oxygen 
therapy is one of the few treatments for patients with 
severe radiation-induced symptoms, which include 
proctitis and cystitis with bleeding. However, evidence 
of its eﬃ  cacy is weak and is based almost solely on small 
retrospective studies. 
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avoiding potential systemic toxic eﬀ ects. The conditions 
in the TIME trial were intended to optimise successful 
MUC1-speciﬁ c T-cell activation. Patients were selected on 
the basis of positive staining of at least 50% of tumour 
cells for MUC1, ensuring that the target was present. 
TG-4010 was delivered concurrently with standard 
chemotherapy to augment the immune response.8 Finally, 
a biomarker based on baseline concentrations of activated 
natural killer cells was validated to further select the 
population likely to respond to the vaccine.
There are many hurdles for successful anticancer 
vaccination.9 An appropriate tumour-speciﬁ c antigen 
must be delivered to dendritic cells, which must have 
received suitable activation signals to allow processing 
and presentation of the antigen. The dendritic cells 
must then travel to lymphoid organs and be at a mature 
stage to trigger an eﬀ ector T-cell response. Even if 
all the necessary steps for successful T-cell activation 
occur, the stimulated T cells must track to the tumour 
microenvironment where they must overcome the many 
immunosuppressive mechanisms used by tumour cells to 
avoid T-cell recognition. One of the likely explanations for 
the failure of previous cancer vaccines is that no strategy 
adequately addressed the immunosuppression side of 
the equation. The success of the checkpoint inhibitors, 
which overcome negative or inhibitory signals on 
T cells, is proof of the importance of addressing tumour-
induced immunosuppression. As suggested by Ribas,10 
the paradigm has shifted from eﬀ orts to stimulate the 
immune response to one of “releasing the brakes” of the 
negative regulation of T cells. 
The TG4010 vaccine and associated biomarker 
investigated in this phase 2b portion of the TIME 
trial6 has shown encouraging results, with improve-
ments in outcomes and minimum toxic eﬀ ects. 
This vaccine strategy and the conditions of the 
phase 3 part of the trial optimise the chance for 
successful T-cell stimulation. Whether this strategy 
alone is enough to succeed without speciﬁ cally 
addressing tumour-induced immunosupression needs 
conﬁ rmation in the phase 3 trial.
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One randomised trial (HORTIS),1 in which hyperbaric 
oxygen therapy is compared with sham treatment in 
120 evaluable patients with chronic radiation-induced 
proctitis, included crossover of patients who had sham 
treatment to hyperbaric oxygen therapy shortly after 
completion of initial treatment. Although a signiﬁ cant 
(albeit modest) improvement on the Late Eﬀ ects 
Normal Tissue scoring system (LENT SOMA) and on a 
bowel bother scale was noted in patients who received 
hyperbaric oxygen therapy, no data on longer-term 
beneﬁ t are available because of the early crossover. 
Results of a small, randomised study2 of hyperbaric 
oxygen therapy versus argon plasma coagulation for 
patients with radiation proctopathy suggested a better 
and faster response with argon plasma coagulation 
than with hyperbaric oxygen. Sucralfate enemas and 
antibiotics are other therapies for radiation proctitis 
with some evidence of eﬃ  cacy.3
Systematic assessment and treatment of chronic 
radiation-induced bowel dysfunction using a 
comprehensive management algorithm,4 has proven 
to be effective in a randomised trial.5 This algorithm 
suggests the use of hyperbaric oxygen therapy for 
patients with rectal bleeding. However, the authors 
of two systematic reviews6,7 of hyperbaric oxygen 
therapy for patients with radiation-related tissue 
injuries concluded that evidence was too limited and 
that more clinical trials were needed to assess both its 
long-term benefit and cost-effectiveness.8
In The Lancet Oncology, Mark Glover and colleagues9 
report the results of the randomised HOT2 trial of 
hyperbaric oxygen therapy versus sham treatment for 
patients with chronic bowel dysfunction after pelvic 
radio therapy. 84 patients were randomly assigned 
(2:1) to receive 40 exposures of hyperbaric oxygen 
therapy or sham treatment in 8 weeks. With changes 
in the bowel component and rectal bleeding score of 
the Inflammatory Bowel Disease Questionnaire from 
baseline to 12 months after start of treatment set as 
the primary endpoint measures, the investigators 
found no evidence of a benefit from hyperbaric 
oxygen therapy.
Mark Glover and colleagues are to be applauded 
for the sham-controlled study design and 12-month 
follow-up in what has been a long-awaited 
confirmatory trial of the efficacy of hyperbaric oxygen 
therapy in this setting. The strength of this study 
is the standardised analysis and treatment guided 
by the Royal Marsden algorithm for all included 
patients, ensuring that patients with other causes of 
bowel symptoms were excluded and given relevant 
treatments. This approach might have led to a 
highly selected study population of patients with 
long-lasting, difficult symptoms, but these are the 
typical patients who would qualify for referral for 
hyperbaric oxygen therapy.
The negative results of the HOT2 trial are dis-
appointing for clinicians and patients who hoped for 
proof of efficacy of hyperbaric oxygen therapy, a form 
of therapy that is often tried as a last resort. Yet the 
publication of negative trial results are important 
to avoid publication bias of efficacy and to give a 
compelling rationale to plan future phase 3 trials. 
The results are especially relevant with respect to the 
burden that undergoing hyperbaric oxygen therapy 
can be for patients (at least 6–8 weeks of daily 
treatments, with risk of [transient] vision changes 
and ear problems) and for health-care providers, 
given the significant cost of hyperbaric oxygen 
therapy.
The mechanism by which hyperbaric oxygen therapy 
is thought to promote the repair of damaged tissue 
is by restoring oxygen tension, which stimulates 
angiogenesis and improves tissue function in chronic 
hypoxic, atrophic, fibrotic, and damaged mucosal 
tissue. One of the secondary endpoints in the 
HOT2 trial was photographic evidence of changes 
in images of rectal mucosa taken through flexible 
sigmoidoscopy; assessment of this endpoint would 
have added essential information about the degree 
of tissue healing and allowed a direct assessment 
of changes in response to hyperbaric oxygen. 
The question remains whether the results of the 
HOT2 trial should be understood as hyperbaric oxygen 
therapy having a transient and too weak an effect 
on the atrophic and vulnerable mucosa to result in 
measurable improvement or whether the results seem 
to refute the putative mechanism by which oxygen 
therapy is thought to promote tissue healing.
The results of the HOT2 trial do, however, give 
compelling and urgent rationale for more well 
designed clinical trials of hyperbaric oxygen 
therapy. Random assignment of patients with 
chronic radiation-induced bowel dysfunction to a 
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The discovery of molecular drivers of carcinogenesis 
has resulted in a large-scale shift in thinking about 
cancer treatment. Advanced non-small-cell lung 
cancer (NSCLC)—once judged a fairly homogenous 
entity and managed uniformly with chemotherapy—
is now perceived as a conglomerate of various 
molecular subtypes that need diﬀ erent treatments. 
Rearrangements of the ALK oncogene are among the 
most intensively investigated molecular targets in 
NSCLC. ALK-rearranged (ALK-positive) disease comprises 
about 4–5% of all cases of NSCLC and is characterised by 
frequent metastatic spread to the pericardium, pleura, 
liver, and CNS. 
The good clinical activity of crizotinib1—the 
ﬁ rst-in-class ALK inhibitor that also targets MET 
and ROS1 proto-oncogenes—raised hopes for a 
breakthrough therapeutic improvement. However, 
enthusiasm for this compound has been tempered 
partly by the inevitable and fairly early emergence of 
acquired resistance. Moreover, penetrance of crizotinib 
through the blood–brain barrier is poor, resulting in 
modest eﬃ  cacy in combating or preventing brain 
metastases.2 Next-generation ALK inhibitors, which 
have the ability to bypass resistance mutations and 
penetrate the blood–brain barrier, fulﬁ l an unmet 
clinical need.
In The Lancet Oncology, Alice Shaw and colleagues3 
present results of a phase 2 trial assessing alectinib, 
a new ALK inhibitor, in 87 patients with advanced 
NSCLC who had previously received crizotinib 
treatment. Notable activity of this compound 
was reported: an objective response was achieved 
by 33 (48%, 95% CI 36–60) of 69 patients with 
measurable disease at baseline according to an 
independent review committee, and median 
progression-free survival was 8·1 months (95% CI 
6·2–12·6). Moreover, alectinib was well tolerated and 
adherence was acceptable. More than half the patients 
had brain metastases at enrolment (52 [60%] of 87), 
almost two-thirds of whom had received previous 
brain radiotherapy. The intracranial response 
to alectinib is noteworthy (21 [40%] patients 
achieved an objective response, including 13 [25%] 
who achieved a complete response) because few 
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sham treatment is difficult, whereas a comparison 
of hyperbaric oxygen therapy to other treatment 
approaches might be more acceptable and enable 
larger trials. All patients with serious chronic 
radiation-induced bowel problems should be assessed 
and managed by an expert multidisciplinary team.4 
Both symptom-related end points and endpoints 
related to tissue healing would be essential in further 
trials of hyperbaric oxygen therapy for radiation 
proctopathy, as symptoms can relapse and remit, 
and proof of the mechanism and degree of tissue 
improvement with hyperbaric oxygen therapy is 
needed.
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